Development of Novel Drugs for the Modulation of Innate Lymphoid Cells (ILCs)

A global pharmaceutical company with a history of successful academic collaborations and cutting-edge capabilities in drug development is looking for research collaboration or funding proposals involving new drug discovery programs related to innate lymphoid cells (ILCs).

Our client wishes to fund projects up to €750k (or $830k if based in North America), focussing on the development of novel drugs and technologies to modulate ILCs.

Further information

Research interests

Our client wishes to fund research focusing on novel targets and potential therapeutics linked to modulating ILCs to either enhance or inhibit the immune response. In order to be funded, successful projects will meet one or more of the following criteria:

• Novel drug targets for the development of therapeutics that modulate ILCs
• Identification of small molecule compounds, antibodies or nucleotides as well as new modalities, (e.g. siRNA and peptides), that can modulate ILCs 
• Validation of the novel drug targets in diseases
• Platform technology to generate multiple projects related to the regulation of ILCs.

Out of scope

• Biomarkers and drug targets related to Natural Killer (NK) cells

Submission information

Please download this linked Application Form with Terms and Conditions to submit an application by 24th February.

Jurisdictions of interest

Worldwide

Desired Outcome

Research projects leading to the generation of therapeutics for clinical development.